On May 3, 2021, Vaxart announced that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1, the companyﾒs first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins, has broad cross-coronavirus activity.